News und Analysen
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, “Iveric Bio”) today announced that on April 29, 2023
Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, is pleased to announce its participation
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
Relief Therapeutics Announces Executive Leadership Team Change
EQS-News: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Uni-Bio Science Group Limited: 2022 Annual Results
EQS-News: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Newron to present at the 31st European Congress of Psychiatry
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Sensorion Reports Full-Year 2022 Financial Results and Business Update
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces today its full-year 2022
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Valbiotis veröffentlicht seine Jahresergebnisse 2022 und gibt ein Update zu seiner strategischen Roadmap
Valbiotis (FR0013254851 – ALVAL, PEA / SME förderungswürdig (Paris: ALVAL), ein kommerziell orientiertes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
Valbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™
Newron Announces 2022 Financial Results and Provides Outlook For 2023
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral